Adult Dosing

• Not applicable for use in adults

Pediatric Dosing

Respiratory distress syndrome

• Initial dose: 2.5 mL/kg birth weight
• Repeat doses: Up to 2 repeat doses of 1.25 mL/kg birth weight q12 hrs may be administered
• Max: 5 mL/kg (sum of initial dose and up to 2 repeat doses)

Note:

• Administered intratracheally by instillation using a 5 French end-hole catheter

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of respiratory distress syndrome (RDS) in premature infants

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Intended for intratracheal use only
• Exogenous surfactants can rapidly affect oxygenation and lung compliance. Hence, the infants receiving therapy should be assessed frequently, both clinically and through investigations, for any respiratory changes so that the oxygen and ventilatory support can be modified to respond to these changes. Poractant alfa should be administered by individuals trained and experienced in the care, resuscitation, and stabilization of preterm infants
• Discontinue treatment and initiate appropriate measures on development of bradycardia, hypotension, endotracheal tube blockage and oxygen desaturation. Once the patient is stabilized, dosing may proceed with appropriate monitoring
• Before initiation of therapy correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia is advised

Pregnancy Category: Not Applicable

Breastfeeding: Not Applicable

• RESP: Endotracheal tube blockage, hypoxia, oxygen desaturation
• CV: Bradycardia, patent ductus arteriosus, hypotension

• Pulmonary surfactant; reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures
• Metabolism: Unknown
• Excretion: Unknown
• Half life: Unknown

US Trade Name(s)

• Curosurf

US Availability

Curosurf

• SUSP: 80 mg/mL (1.5, 3 mL vials)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Curosurf

UK Availability

Curosurf

• SUSP: 80 mg/mL (1.5, 3 mL vials)

Australian Trade Name(s)

• Curosurf

Australian Availability

Curosurf

• SUSP: 80 mg/mL (1.5, 3 mL vials)

[Outline]

Pulmonary

Lung Surfactants